Acalabrutinib Maintenance Following Cellular Therapy for Large B-Cell Lymphoma Patients at Very High Risk for Relapse
Jonsson Comprehensive Cancer Center
Summary
This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lymphoma at very high risk of the cancer coming back. Acalabrutinib is a small molecular inhibitor that may interfere with the ability of cancer cells to grow and spread.
Description
PRIMARY OBJECTIVE: I. To determine the safety and tolerability of maintenance acalabrutinib following cellular therapy in participants with large B-cell lymphoma at very high risk for relapse. SECONDARY OBJECTIVES: I. To estimate the effectiveness of maintenance acalabrutinib following cellular therapy in participants with large B-cell lymphoma at high risk for relapse. II. To estimate the durability of remission after completion of acalabrutinib maintenance. III. To estimate survival following completion of acalabrutinib maintenance. IV. To estimate the rate of conversion from partial re…
Eligibility
- Age range
- 18–70 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Ages 18-70 years * One of the following: * Patients undergoing autologous stem cell transplantation (ASCT) or any Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR) T-cell therapy product for: * High grade B-cell lymphoma (double or triple hit) with rearrangements in bcl-2 and/or bcl-6, and rearrangement in myc * Large B-cell lymphoma with a history of secondary CNS involvement * Histologic transformation of indolent lymphoma to large B-cell lymphoma, including marginal zone lymphoma, follicular lymphoma, chronic lymphocytic leuke…
Interventions
- DrugAcalabrutinib
Given PO
Locations (3)
- UCLA / Jonsson Comprehensive Cancer CenterLos Angeles, California
- University of California Davis Comprehensive Cancer CenterSacramento, California
- University of OklahomaOklahoma City, Oklahoma